Jefferies Financial Group Inc. Takes Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Jefferies Financial Group Inc. bought a new position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 15,048 shares of the company's stock, valued at approximately $332,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in TEVA. Oarsman Capital Inc. bought a new position in shares of Teva Pharmaceutical Industries during the 4th quarter valued at $29,000. Marshall & Sterling Wealth Advisors Inc. purchased a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at about $44,000. Ameliora Wealth Management Ltd. purchased a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at about $66,000. IFP Advisors Inc boosted its position in Teva Pharmaceutical Industries by 96.1% during the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock valued at $88,000 after buying an additional 1,960 shares during the period. Finally, Quadrant Capital Group LLC boosted its position in Teva Pharmaceutical Industries by 27.7% during the fourth quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock valued at $96,000 after buying an additional 949 shares during the period. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Trading Down 1.2%

Shares of Teva Pharmaceutical Industries stock traded down $0.21 during trading on Wednesday, reaching $16.58. 12,519,318 shares of the stock were exchanged, compared to its average volume of 10,002,806. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The stock's fifty day moving average is $15.37 and its 200 day moving average is $17.38. The firm has a market cap of $18.79 billion, a price-to-earnings ratio of -11.43, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62. Teva Pharmaceutical Industries Limited has a 1 year low of $12.47 and a 1 year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. The company had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Teva Pharmaceutical Industries's revenue for the quarter was up 1.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.48 earnings per share. As a group, equities research analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have issued reports on TEVA. UBS Group cut their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and lifted their target price for the stock from $21.00 to $23.00 in a research note on Monday, May 12th. Bank of America lifted their target price on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Barclays decreased their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. Finally, Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of "Buy" and a consensus target price of $24.43.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.